Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New Psoriatic Patients May Have Lower Serious Infection Risk With IL-12/23 Inhibition

Key clinical point: Psoriasis or psoriatic arthritis with previous exposure to biologics had no significant difference in serious infection risk based on biologic type.

Major finding: The risk of serious infection was 41% lower in biologic-naive patients treated with an interleukin-12/23 inhibitor, compared with those treated with TNF inhibitor.

Study details: The data come from a retrospective study of 11,560 treatment episodes for psoriasis or psoriatic arthritis in 9,305 adults.

Disclosures: The study was supported by the Center for Drug Safety and Effectiveness at the Johns Hopkins Bloomberg School of Public Health. The researchers had no financial conflicts to disclose.

Citation:

Li X et al. Ann Rheum Dis. 2019 Oct 31. doi: 10.1136/annrheumdis-2019-216102.